CLINICAL_TRIALS
withdrawal
· 2012-01-18
Clinical Trial Update: Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD [Phase 3]
Summary
A Phase 3 trial evaluating double-dose rabeprazole for symptom control in non-erosive gastroesophageal reflux disease was withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Inje University | Conditions: Gastroesophageal Reflux Disease | Phase 3 | Status: WITHDRAWN